Purpose: This study was designed to determine whether DNA methylation biomarkers are associated with recurrence and survival in colon cancer patients.
Introduction
Colorectal cancer remains the third most common malignancy and the second leading cause of cancer mortality for both men and women combined in the United States (1) . Despite curative surgical resection, it is reported that 20% to 50% of all patients with American Joint Committee on Cancer (AJCC) stage II or III colon cancer will develop disease recurrence; 80% of all recurrences occurring within the first 3 years following surgical resection (2) . Historical controls indicate that the absolute benefit for adjuvant 5-flurouracil (5-FU)-based chemotherapy in all stage II patients is minimal (3) .
Accepted clinicopathologic risk factors for stage II colon cancer patients at high-risk of recurrence include T4 disease (tumor perforation or invasion of an adjacent organ), identification of less than 12 lymph nodes in the surgically resected specimen, microvascular invasion, and poorly differentiated histology (4) (5) (6) . In this select group of stage II patients, discussion of the possible benefits of adjuvant chemotherapy is encouraged but largely remains up to the discretion of the treating physician and patient (7) .
In stage III patients, the 5-year overall survival (OS) rate varies widely from 28% to 60% (2) , indicating that a significant amount of tumor heterogeneity exists and that the current clinical staging system does not necessarily reflect the tumor's biologic behavior. Although the AJCC staging system (version 7) has been revised, predictive and prognostic markers were not included for locally advanced disease and remain an area under continued development.
Currently, all stage III disease patients and select stage II disease patients are considered for either 6 months of adjuvant 5-FU and leucovorin (LV) or a combination of oxaliplatin, infusional 5-FU, and LV (FOLFOX) yielding an absolute OS rate benefit of less than 3% and 10%, respectively (3, 8) . Unfortunately, few chemotherapy advances have developed for the treatment of locally advanced colon cancer. Furthermore, despite the use of novel moleculartargeted therapeutics (i.e., bevacizumab, cetuximab, and panitumumab) in patients with metastatic disease, their use in stage II and III patients is not supported at this time. Recent results from 3 phase III trials were negative. The NSABP C-08 trial of FOLFOX AE bevacizumab (stage II and III) and the N0147 trial of FOLFOX AE cetuximab (stage III only) failed to determine any additional benefit beyond standard FOLFOX for an improvement of disease-free survival (DFS; refs 9, 10). Preliminary results from the international phase III AVANT trial (11) of adjuvant FOL-FOX or FOLFOX þ bevacizumab or XELOX þ bevacizumab also failed to meet the primary endpoint of DFS with improved outcomes for the control arm. The results from these phase III trials clearly indicate that the underlying biology in locally advanced colon cancer is dissimilar from that of metastatic colon cancer.
Thus, for the time being a therapeutic plateau in locally advanced colon cancer has been reached. Identification of a contemporary biomarker for recurrence risk, OS, and potential therapeutic benefit would result in optimal clinical management of locally advanced colon cancer patients.
Colon cancer is clearly a molecularly diverse cancer given the variability in OS and recurrence (12) . Many studies have explored the prognostic value of various molecular markers in both early and advanced colorectal cancer (13) (14) (15) . Although a series of molecular markers for colorectal cancer is available for clinical use, many are still being validated in ongoing clinical trials and currently none are conventionally accepted for locally advanced colon cancer. Recent data has indicated that the presence of the K-ras mutation is likely not prognostic, but is predictive of potential benefit of molecular-targeted therapy. Currently, K-ras is the only validated predictive marker for colon cancer, but its role is limited to the setting of metastatic disease (16) .
Epigenetic aberrations have been reported to be important mechanisms in human carcinogenesis (17) (18) (19) . Inactivation of tumor suppressor genes by promoter hypermethylation has been implicated in colorectal carcinogenesis (20) . Prior studies have indicated the predictive and prognostic utility of gene methylation in primary colorectal tumors (21) (22) (23) . However, it is still unclear whether the methylation profile of tumor suppressor genes can serve as prognostic biomarkers for tumor recurrence and survival in patients with colon cancer following curative surgical resection.
Promoter hypermethylation of tumor suppressor genes including CHFR (checkpoint with forkhead-associated and RING finger domains), ID4 (inhibitor of DNA binding), and RECK (reversion-inducing cysteine-rich protein with Kazal motifs) has been reported in colorectal cancer and is associated with reduced mRNA and/or protein expression (24) (25) (26) . In this study, we evaluated select tumor suppressor genes and the MINT1 (methylated-in-tumor) locus (27) to analyze the association of tumor recurrence and patient OS with methylation status.
Materials and Methods

Patient enrollment and tissue samples
In a single-institution retrospective analysis, we evaluated patient records from 82 patients with histologically confirmed (AJCC version 6) high-risk stage II (T 3-4 N 0 ) or III (T x N þ ) colon adenocarcinomas. High-risk stage II was defined as T4, poorly differentiated histology, less than 12 lymph nodes dissected, and evidence of lymphovascular invasion. Patients with rectal cancer and/or known familial colorectal cancer syndromes were excluded. All patients had undergone curative surgical resection without prior chemotherapy at The University of Texas MD Anderson Cancer Center (Houston, Texas) from December 1999 to August 2007. All tissue specimens were randomly provided by the MD Anderson tissue bank based on eligibility criteria and available primary colon tumor tissue and adjacent normal colonic mucosa. Charts were reviewed using all available electronic medical records and data on tumor recurrence, OS, and clinicopathologic characteristics. All patients had previously provided preoperative informed consent to allow their surgical tissue specimens to be used for investigational purposes. This study was approved by the institutional review board of MD Anderson Cancer Center.
DNA methylation analysis
DNA methylation levels were measured using the highly quantitative pyrosequencing technology (Pyrosequencing AB, Sweden). Surgical specimens were frozen in liquid nitrogen and stored at À80 C, and subsequently used for the extraction of tissue DNA. The same tumor samples were evaluated by hematoxilin-eosin staining to confirm that the dissected area contained more than 50% of tumor cells in all cases. Lymphocyte DNA was extracted from blood samples donated by healthy donors and served as the negative control. DNA purification kits (Promega) were used for DNA extraction. To create a positive control, lymphocyte DNA was treated with CpG Methyltransferase (SssI; New England Biolabs). Each genomic DNA was treated with bisulfite using an Epitect Bisulfite Kit (QIA-GEN). Bisulfite-treated DNA (50 ng) was amplified with gene-specific primers in a 2-step PCR. The second step of PCR was used to label single DNA strands with biotin using a universal primer tag (28) . PCR was performed in a total volume of 25 mL of 2 mmol/L magnesium chloride (MgCl 2 ), 0.2 mmol/L of deoxyribonucleotide triphosphates (dNTPs), 200 nmol/L PCR primers, and 1.25 U AmpliTaq gold DNA Polymerase and GeneAmp PCR Gold Buffer (Applied Biosystems). The PCR primer sequences
Translational Relevance
This study demonstrates that CHFR hypermethylation is significantly associated with disease recurrence in American Joint Committee on Cancer (AJCC version 6) stage III colon cancer after curative surgical resection. Identification of patients with high risk of disease recurrence may have implications for clinical management of colon cancer following curative surgical resection. Our analysis indicates that CHFR methylation status is a potential prognostic biomarker for colon cancer recurrence.
and annealing temperatures are listed in Table 1 . All primers were designed to assay the methylation status of 3 to 4 CpGs in promoter regions within 0.6 kb from the transcription start sites. The following conditions were used in both PCRs: initial denaturation at 95 C for 10 minutes, followed by 48 cycles for denaturation at 94 C for 15 seconds, annealing at the appropriate temperature for 30 seconds, and extension at 72 C for 30 seconds. The touchdown method was used only for MINT1 amplification. To overcome PCR bias, the optimal annealing temperature for PCR in each primer set was determined by testing some mixed rates (0%, 25%, 50%, 75%, and 100%) of positivecontrol DNA in negative-control DNA (29) . After PCR, the biotinylated strand was captured on streptavidin-coated beads (Amersham Bioscience), incubated with the sequencing primers (Table 1) , and run on the PSQ HS 96 pyrosequencing system and Pyro Gold CDT Reagents (Biotage, Sweden), as described previously (28) . Pyrosequencing can measure the methylation levels of several CpG sites in a given promoter. The methylation levels were averaged to represent the degree of methylation in each sample for the tested genes. We defined the mean methylation level of 15% or more as methylation positive because values of 15% or less are difficult to distinguish from background noise.
Immunohistochemistry of MLH1 and CHFR
Formalin-fixed, paraffin-embedded tissues were cut into 3 mm sections consecutively. Immunohistochemistry (IHC) of MLH1 was performed on an automated immunostainer (Lab Vision Autostainer 360-2D; LabVision) according to the manufacturer's protocols. Slides were incubated with the primary antibody for MLH1 (G168-15, BD Bioscience) with a dilution of 1:50 for 1 hour, and followed by Peroxidase staining using Lab Vision UltraVision LP Large Volume Detection System HRP Polymer (Ready-to-Use). Each case was evaluated and categorized into MLH negative or positive. CHFR protein expression was measured using the primary anti-CHFR polyclonal antibody (12169-1-AP, Proteintech Group) at a dilution of 1:150. Sections were incubated with the primary antibody at room temperature for 3 hours, followed by incubation with the secondary antibody at room temperature for 1 hour. The antibody complex was detected using an avidin-biotin-peroxidase complex solution and visualized using 3,3 0 -diaminobenzidine (Zymed Laboratories, Inc.). A negative control was included in each experiment by omitting the primary antibody. The expression level of CHFR was evaluated and categorized into 4 groups; negative, low, medium, and high.
The person who conducted the IHC assay was blinded to the methylation status of the samples.
Statistical methods
Seventy-nine was the minimum sample size required for the Cox proportional hazards model, based on a power of 90%, a ¼ 0.05 (2 sided), standard deviation of 0.50, and The association of methylation status with recurrencefree survival (RFS) or OS was analyzed using the log-rank test, Kaplan-Meier plot, and Cox proportional hazards regression models. The multivariate analysis included clinicopathologic factors that had a P < 0.10. Chi-square test or Fisher's exact test was used to analyze the relationship between methylation status, protein expression level, and clinicopathologic variables. To identify cutoff values that had the highest sensitivity and specificity to predict recurrence, receiver operating characteristic (ROC) analysis was used. All statistical testing was conducted with SPSS software, version 17.0 (SPSS Inc.). P < 0.05 was considered statistically significant. Table 2 demonstrates the association of clinicopathologic characteristics with tumor recurrence or OS. The median age of the 82 patients was 63.1 years (range, 31-93). NonHispanic whites accounted for 78% of the patients. The mean number of lymph nodes dissected AE standard error, was 25.6 AE 2.6 (range: 6-190); 10 cases had less than 12 dissected lymph nodes. Adjuvant 5-FU-based chemotherapy was provided in 61 (74%) patients; FOLFOX was concurrently administered to 18 patients with stage III disease. After a mean follow-up of 60 months, disease recurrence developed in 24 (29%) patients and 12 (15%) had died. Common sites of disease recurrence included liver (67%), lung (25%), peritoneum (4%), and the primary tumor (4%). T4 stage was associated with reduced RFS and OS (P ¼ 0.013 and P ¼ 0.038, respectively, log-rank test). Patients with proximal-sided tumors were noted to have a reduction in OS (P ¼ 0.048).
Results
Patient demographics and tumor clinicopathologic features
Association of DNA methylation with OS and RFS
In the pyrosequencing assay, lymphocyte DNA and adjacent normal tissue DNA were shown to be methylation-negative (<15%). Methylation-positive rates (!15%) for CHFR, ID4, MINT-1, and RECK in tumor DNA were 63%, 46%, 28%, and 9%, respectively. Methylation status was not significantly associated with RFS or OS in any of the tested genes or in the MINT1 locus (Table 3) . When ROC analysis was used to separate all cases into 2 prognostic groups, a cutoff value of 30% for CHFR methylation level recurrence was noted with 62.5% sensitivity and 65.5% specificity. Therefore, we dichotomized the methylation status into methylation-negative or -low (<30%) and methylation-high (!30%). Patients with CHFR methylation-high status had a significantly reduced RFS and a trend toward reduced OS (P ¼ 0.006 and P ¼ 0.069; Table 3 , log-rank test). Kaplan-Meier plots indicated that the probability of RFS at 5 years was 0.55 AE 0.09 in the CHFR methylation-high group and 0.82 AE 0.06 in the CHFR methylation-negative or -low group (P ¼ 0.006, Fig. 1A ). Subgroup analysis showed that CHFR methylation-high status was associated with reduced RFS (P ¼ 0.004, Fig. 1B ) and reduced OS (P ¼ 0.010) in stage III disease patients, whereas no association with RFS was observed in high-risk stage II disease patients (P ¼ 0.661, Fig. 1C ).
Association of methylation status with clinicopathologic characteristics
We analyzed the relationship between methylation status and clinicopathologic factors. CHFR methylation-high status was significantly associated with age 70 years or more, proximal tumor, and N2 disease (P ¼ 0.008, P ¼ 0.002, and P ¼ 0.04, respectively; Table 4 ). Methylationpositive status in both ID4 and MINT-1 was associated with poorly differentiated tumors (P ¼ 0.001 and P < 0.001).
MLH1 protein expression
IHC analysis demonstrated that 15/65 (23%) of tissue samples examined were negative for MLH1 staining (Fig. 2) . The MLH1 staining status was not associated with CHFR hypermethylation (P ¼ 0.928).
Correlation of CHFR methylation status with protein expression
CHFR protein expression was detected in 30/35 (86%) of the tissue samples analyzed (Fig. 3) . The expression level was low in 10 (29%), intermediate in 11 (31%), and high in 9 (26%) of the 35 samples. CHFR expression level was inversely associated with CHFR methylation score (P ¼ 0.008); 12 of 19 (63%) cases with methylation-high (!30%) had negative or low protein expression level, whereas 13 of 16 (81.3%) cases with CHFR methylationnegative or -low had medium or high protein expression levels.
Multivariate analysis
We used the Cox proportional hazards model for multivariate analysis on RFS (Table 5 ). In all patients (n ¼ 82), CHFR methylation-high status was an independent 
Discussion
Our current data indicates that the methylation level of CHFR measured by pyrosequencing assay was an independent predictor for recurrence for locally advanced colon cancer patients. By subgroup analysis, CHFR methylationhigh was associated with reduced RFS and OS, notably in stage III patients. Though it is well established that stage III colon cancer patients have a relatively high disease recurrence rate (30%-40%) regardless of the completion of adjuvant chemotherapy (31), our results indicate that CHFR methylation status may be a useful prognostic biomarker in stratifying patients for more intensive treatment or surveillance.
CHFR was initially identified as an early mitotic checkpoint protein that delays entry into metaphase of the cell cycle in response to mitotic stress caused by microtubule inhibitors (32) . Thereafter, some studies have established that CHFR mRNA expression was lost or decreased in primary tumors and cell lines of colorectal cancer (24), gastric cancer (33), lung cancer (34) , and oral squamous cell carcinoma (35) ; this was predominantly mediated through DNA methylation of the CHFR promoter (24, (33) (34) (35) . In addition, Yu and colleagues reported that CHFR knockout mice are prone to carcinogenesis (36) . These findings suggest an important role of CHFR as an inhibitor of tumorigenesis through regulation of the cell cycle and maintenance of genomic stability.
In our analysis, CHFR promoter methylation was associated with advanced lymph node metastasis (N2). Privette and colleagues demonstrated that low expression of CHFR in human mammary epithelial cells resulted in malignant progression, increased motility, and enhanced invasiveness (37) . In prior colorectal cancer studies, low or lost CHFR expression has been associated with a high mitotic index (24) , and the checkpoint function of the forkheadassociated domain is a core component of anti-proliferative properties against gastrointestinal carcinogenesis (38) . These data suggest that an epigenetic inactivation of CHFR correlates with increased malignant potential of colon cancer.
To date, we are unaware of any published reports demonstrating an association of CHFR methylation level with colon cancer recurrence as observed in our analysis. Two important studies on CHFR function have been recently published. Kashima and colleagues demonstrated that CHFR significantly downregulated IL-8 through the inhibition of nuclear factor kB (NFkB) and that the migration of human endothelial cells was suppressed in the culture medium conditioned from CHFR-expressing cancer cells (39) . In a separate study, Oh and colleagues demonstrated that CHFR downregulated histone deacetylase 1 (HDAC1), leading to upregulation of the Cdk inhibitor, p21, and tumor suppressor genes, KAI1 and E-cadherin (40) . Taken together, these data support a potential role of CHFR for regulating cancer metastasis. Microsatellite instability (MSI)-high or dMMR (deficient mismatch repair) phenotype of colon cancer occurs infrequently (15%-20%) and is reported to be associated with CHFR hypermethylation (41) or its decreased protein expression (42) . It has been also noted that MSI-high colon cancer patients have an overall improved prognosis regardless of stage and do not benefit from single-agent 5-FU (43) (44) (45) ; in fact, if stage II patients are treated with single agent 5-FU they may fare worse for OS (23, (43) (44) (45) . Although we observed no association between CHFR methylation and MLH1 expression, these previously reported findings appear to be inconsistent with our observation that CHFR hypermethylation correlates with low RFS. Controversy remains when discussing the role adjuvant oxaliplatin-based chemotherapy (FOLFOX) in patients with MSI-high stage III colon cancer (13, 45) . Additional assessment of the association of CHFR hypermethylation, adjuvant chemotherapy, and MSI status relative to prognosis (RFS and OS) in a larger patient population is warranted to understand the potential effects and interactions of these factors.
The CpG island methylator phenotype (CIMP) has been named as a distinct molecular colon cancer subgroup that is fundamentally different from other colon cancers (46) , and this subtype has been reported to be a prognostic marker of improved OS in colon cancer, according to several studies (23, 47) . Although some clinical and molecular (38) characteristics such as high frequency of proximal tumors and MSI have been associated with both CIMP-positive status and CHFR hypermethylation (23, 41, 48) , CHFR methylation has not been clustered with CIMP-positive subtype in those studies (23, 41, 47) , suggesting the possibility that methylation of CHFR is independent of CIMP.
In our analysis, a cutoff value of 15% was used to define a positive methylation status. An absolute cutoff value of methylation-positive status in a pyrosequencing assay is nonexistent. In addition, methylation status was categorized into 2 groups: methylation-negative or -low (<30%), and methylation-high (!30%) based on ROC analysis for prediction of recurrence. Considering that CHFR methylation-high (!30%) was significantly associated with negative or low expression level of CHFR in this study, the cutoff value of 30% is functionally justified for CHFR methylation. Pyrosequencing is a highly reproducible and accurate quantitative assay. Indeed, a method of grouping patients by the extent of methylation has previously been used for improved prognostic stratification (49, 50) .
No association of methylation status in ID4, MINT1, or RECK with RFS and OS was observed in our study. ID4 has been thought to act as a dominant-negative inhibitor of gene transcription and to regulate important pathways in cell proliferation and differentiation (22) . Hypermethylation of ID4 promoters has been reported to correlate with poorly differentiated tumors and poor OS in a colon cancer study (22) . In our study, methylation-positive status of ID4 was associated with poorly differentiated tumors but not with OS and RFS. MINT1 has been defined as one of the CIMP markers (21) . CIMP status has been associated with survival of colon cancer patients (21, 23) , but it is unclear whether the single effect of MINT1 has significant impact on outcome (20) . RECK is an important metastasis suppressor gene, and its epigenetic inactivation has been reported to enhance invasion of human colon cancer cells (26) . To date, no association of RECK hypermethylation with recurrence and survival has been demonstrated.
We realize our study's limitations: it is a retrospective, single-institution analysis and is limited by sample size. We also recognize the tissue specimen collection spanned over a 9-year duration which may seem prolonged, but was limited by availability of tissue based on the eligibility criteria. In this analysis, only 1/3 of patients were stage II, resulting in a limited sample size for this subgroup analysis. The greater number of stage III patients reflects the more commonly referred patient population to MD Anderson, of more advanced stage patients. However, these findings provide early insight regarding CHFR hypermethylation and development of disease recurrence in AJCC stage III patients. A larger population analysis will need to be conducted for further validation. If confirmed, methylation status of CHFR may be not only an informative prognostic biomarker to identify patients with increased risk of recurrence, but also a biomarker for therapeutic development. Considering few therapeutic modifications have developed in the management of these patients, identification of additional biomarkers may be of added significance. Hypermethylation may serve as a selected treatment approach, as preclinical and clinical studies have indicated the potential role of hypomethylating agents, such as azacitidine (AZA), in reversing the effects of hypermethylation in solid tumors (51) . We are currently conducting a single institution phase I/II study evaluating the role of AZA in combination with oxaliplatin and capecitabine in CpG hypermethylated (MSI-high) metastatic colorectal cancer patients that are refractory to standard therapy.
In summary, we observed a significant association between the extent of CHFR methylation level in stage III disease and the development of disease recurrence. We realize that disease recurrence may be attributable to a multitude of factors, and it is likely there are other undetermined or yet-to-be validated prognostic and predictive markers. Nevertheless, we believe this epigenetic biomarker may have an integral role in disease development and recurrence, and its therapeutic development and significance may be of greater magnitude when combined with other potential biomarkers. 
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